Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,481–1,490 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1481
- Medicine slug
- tenofovir-disoproxil
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 18
- Source count
- 18
- Agreement rate
- 1
- Recorded readings
1.3 ± 0.6 L/kg
- Numeric value
- 1.3
- Unit
- L/kg
- Source records
- 18
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 18 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e0e1b7-6a45-4d63-b569-00826832c25a (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1 mg/kg and 3 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08a30772-02fc-4f63-e063-6394a90afd43 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1 mg/kg and 3 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c7d72d6-bf80-49e0-921c-20169e87e62f (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3285f345-e58d-4831-a6a8-31094c8c546d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de27413a-6579-4586-80dc-39c712652952 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcd3120b-60f6-41d8-a512-ed4a62c836b4 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0ae0aa2-3baa-4b75-9e85-68b5338c3c14 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:532755cb-1cd3-4774-97af-05a53779b65f (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a75c6be8-3719-4bb3-8a9e-06e5254d2a82 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f0bc342-0a0a-1d28-e053-2991aa0a28b9 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1 mg/kg and 3 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaeb1670-4e39-4541-8ff7-47057f3f5c36 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1 mg/kg and 3 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ac4c628-f01f-42d4-b8e6-d12273aefc6d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1 mg/kg and 3 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33fd6418-fbdc-42ca-a50d-ce2a476a5418 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9cf11bd3-01b9-4ac8-96cc-55d57998b51d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18285dda-d63f-4f0e-821f-a4f2df335c35 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1 mg/kg and 3 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92569e53-507e-7a5b-e053-2995a90aca35 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da78a5d3-f5c6-47fe-b593-3252704c225d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a215f64c-84de-0649-e053-2a95a90a9d59 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.
Projected row 1482
- Medicine slug
- terazosin
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 47
- Source count
- 47
- Agreement rate
- 0.978723
- Recorded readings
12 hours
- Numeric value
- 12
- Unit
- hours
- Source records
- 46
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 46 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27f8952a-189d-4687-854e-c51da619bf3d (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85e450c2-1bc3-49f4-ac2b-5aeedc154bba (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dabd4d6-3023-460a-8577-08b3690e7c93 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d8fd052-b478-447e-a884-74fcd21275bb (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c55d942-35c1-46f6-af89-2a0f68f3ea99 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77e01f71-f6d8-4bbe-b13e-352c7af6b1ef (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d971811c-d327-4e63-808c-8d553ee471e7 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81d5422c-ff57-4f6d-927c-5de4dd7e1169 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:854b64ff-c138-45af-9cdf-6c23323d8490 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1718217-ddab-4a3a-a862-8c952fd5a274 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e7b27a6-cc09-407e-e053-2a95a90a17b3 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:363a6c85-e5e9-4521-9065-37a7c45bb525 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40e5ae44-708a-15a3-e054-00144ff8d46c (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2137488-8554-e84f-e053-2995a90a796c (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c42171e-1b44-4d34-b6ca-5b6a94f0e694 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b4c58a-13ad-48d9-9796-b27fedab6249 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43e92495-2cf2-46dd-a80c-f0c3c88c7b73 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3a5901a-6395-4030-a27b-1fb17cd97315 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cbd8853-718d-42ba-bc27-e3983eefb804 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bed99c2a-4266-4a2c-bb0f-7643fdafff78 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5507ea6-bdb3-4363-a68b-0478cbb25f4a (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0574d9ae-04da-4cb2-b124-9d920012c411 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f2db826-182d-4dd1-af97-f874b57b1fb9 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a16abe41-98e7-4e60-8c1b-911c6a29f0a2 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cdbb03d-0ac9-477b-88f6-5d9492277048 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9199083d-403f-4c9e-90e1-713ed0a07903 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:130c84dc-b598-660f-e063-6294a90a8e46 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4007dbd3-e850-43e7-8a56-8735e31063cd (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d7779b3-02c5-4a74-a749-82ed6ae2c9bc (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:521e4aad-c6ec-4410-867f-dd9ecc08d5b2 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb88f0d9-e010-4d4d-8465-bcccce0bef6e (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:458b4a60-b2d6-445a-8638-7fcd07decf66 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:242589f0-0c79-4ea1-b900-10bccfec2b82 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:916cf0fa-8e39-4b4d-b564-a16aa8511ff6 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:214d9b06-8d23-3ee8-e063-6394a90a1521 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b195327-10d4-477f-ada2-d62c7f835e6c (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff0efbc2-d7aa-9783-e053-6394a90a384f (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b77a4a38-edb1-412e-97af-d49e862b32c1 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da4ca0f8-6888-447e-9948-d37196c5a19a (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4614e8cc-c922-4c0f-e063-6394a90a8501 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57125b47-2156-181c-e063-6394a90ad763 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83bf40fa-6ae1-4811-8dc1-e8c0bcd63d78 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33699a94-4561-455f-9e5d-48856369aa07 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a78f74ce-1c53-41ea-878e-13674db10a67 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3822068f-f160-4493-a207-4d75dad6af73 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5680d373-0f61-baf8-e063-6394a90ab8a6 (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
The plasma levels peak about one hour after dosing, and then decline with a half-life of approximately 12 hours.
13 hours
- Numeric value
- 13
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69582e0c-6569-490c-8c14-999f3750336f (opens source in a new tab)
Terazosin label
Version not recorded · Effective date not recorded
Elimination Terazosin has a half-life of approximately 13 hours.
Projected row 1483
- Medicine slug
- terbinafine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 71
- Source count
- 38
- Agreement rate
- 1
- Recorded readings
36 hours
- Numeric value
- 36
- Unit
- hours
- Source records
- 38
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 38 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab6f50a5-87ce-0819-e053-2a95a90a22b7 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f87e3e1-4c9c-497a-af20-8ab52cfeef60 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f6d7b1a-5a01-4cc5-b5b7-c126ae889557 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53235270-6ffb-44c8-aa55-debf59e1d964 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34221c17-0d8c-4b56-8af3-c74efab4599e (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:838c6140-19b6-4c2b-aed7-3065bd67af07 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cacf5fe4-8c24-47ed-9a2b-b70aa5d45ef2 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584d1fae-0120-49a0-e063-6394a90a36fc (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.Terbinafine is distributed to the sebum and skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:715cae3e-4e86-48b3-e053-2a95a90afdc2 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6600e2b3-65df-4fc3-8081-d574537d27e3 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:294bc1af-50e3-4bff-8d48-321e673033ce (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a921005-304e-4f5b-b9ba-681749e2499b (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2df111dc-ecac-4161-9e22-38436eb37c1f (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d01fde5-e4cf-6670-e053-2991aa0a5b15 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79a39fb1-12b7-4b1e-9f28-102af34d0459 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6dc279cc-9861-4fa8-8083-ca3b3c57b513 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3925dc10-ad66-46a8-bfa5-1a4314be3521 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:808dab18-43f1-4895-a023-edbde722863e (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a54cc4f-0789-46ce-875f-df759aa95d9c (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:747fdc13-7c3a-4672-b50c-31c51037bda2 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b43e4644-024c-4aa6-b403-19152c785802 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17e976c6-ee44-42c5-987f-5360ee6d7c1e (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2ecf7a5-1c84-4977-8a87-d1bfb9658668 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79ddc2e9-ea43-41a2-a5b0-b13b3eaf7d7a (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ee1b667-0cf6-46e4-a740-4fc27904d577 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2886b2ff-815f-4621-bc28-1fea082c1920 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e515f99-7fc7-4692-9105-8e87c27d4e79 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87af930f-493c-590e-e053-2a95a90a804a (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7cf55e2-f637-e2d9-e053-2995a90a6270 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:085e0809-6b7f-447e-976e-8276c29daad6 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0b309a5-bebe-c6da-2847-bda21aa488b1 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6605103b-fd71-4438-8496-f48973b98901 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44c6f6e7-e0c0-450e-83ce-1ed4f3efddec (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ea693ec-e2f2-4661-b144-17651018e9fb (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5de4c245-7086-453b-b90a-7a1242ec2c0b (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50657431-1cd9-42dd-9cfc-57db8713d267 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3832113-f517-4b4e-bf9c-31fce1a638e1 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18b16aad-1877-4b07-b532-f0ef4843af91 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
Projected row 1484
- Medicine slug
- terbinafine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 71
- Source count
- 38
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 38
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 38 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab6f50a5-87ce-0819-e053-2a95a90a22b7 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg∙h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f87e3e1-4c9c-497a-af20-8ab52cfeef60 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f6d7b1a-5a01-4cc5-b5b7-c126ae889557 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53235270-6ffb-44c8-aa55-debf59e1d964 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34221c17-0d8c-4b56-8af3-c74efab4599e (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:838c6140-19b6-4c2b-aed7-3065bd67af07 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cacf5fe4-8c24-47ed-9a2b-b70aa5d45ef2 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584d1fae-0120-49a0-e063-6394a90a36fc (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:715cae3e-4e86-48b3-e053-2a95a90afdc2 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6600e2b3-65df-4fc3-8081-d574537d27e3 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:294bc1af-50e3-4bff-8d48-321e673033ce (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a921005-304e-4f5b-b9ba-681749e2499b (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2df111dc-ecac-4161-9e22-38436eb37c1f (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg∙h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d01fde5-e4cf-6670-e053-2991aa0a5b15 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 μg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 μg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79a39fb1-12b7-4b1e-9f28-102af34d0459 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6dc279cc-9861-4fa8-8083-ca3b3c57b513 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3925dc10-ad66-46a8-bfa5-1a4314be3521 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:808dab18-43f1-4895-a023-edbde722863e (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a54cc4f-0789-46ce-875f-df759aa95d9c (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:747fdc13-7c3a-4672-b50c-31c51037bda2 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b43e4644-024c-4aa6-b403-19152c785802 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg∙h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17e976c6-ee44-42c5-987f-5360ee6d7c1e (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg∙h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2ecf7a5-1c84-4977-8a87-d1bfb9658668 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg∙h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79ddc2e9-ea43-41a2-a5b0-b13b3eaf7d7a (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ee1b667-0cf6-46e4-a740-4fc27904d577 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2886b2ff-815f-4621-bc28-1fea082c1920 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e515f99-7fc7-4692-9105-8e87c27d4e79 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87af930f-493c-590e-e053-2a95a90a804a (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7cf55e2-f637-e2d9-e053-2995a90a6270 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:085e0809-6b7f-447e-976e-8276c29daad6 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0b309a5-bebe-c6da-2847-bda21aa488b1 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 μg/mL appear within 2 hours after a single 250 mg dose; the AUC (area under the curve) is approximately 4.56 μg.h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6605103b-fd71-4438-8496-f48973b98901 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg∙h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44c6f6e7-e0c0-450e-83ce-1ed4f3efddec (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ea693ec-e2f2-4661-b144-17651018e9fb (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg·h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5de4c245-7086-453b-b90a-7a1242ec2c0b (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50657431-1cd9-42dd-9cfc-57db8713d267 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg•h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3832113-f517-4b4e-bf9c-31fce1a638e1 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg∙h/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18b16aad-1877-4b07-b532-f0ef4843af91 (opens source in a new tab)
Terbinafine label
Version not recorded · Effective date not recorded
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
Projected row 1485
- Medicine slug
- terbutaline
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
103%
- Numeric value
- 103
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:859267c6-3d14-4123-9b9d-4fc248f09726 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
The mean (SD) AUC (0-48) values were 54.6 (26.8) and 53.1 (23.5) hr•ng/mL, and corresponded to a bioavailability of 103% for the tablet relative to the solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a95bc4f-34d3-4b5e-841b-6839e1c1e0c7 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
The mean (SD) AUC (0-48) values were 54.6 (26.8) and 53.1 (23.5) hr•ng/mL, and corresponded to a bioavailability of 103% for the tablet relative to the solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:382dcebb-6e41-4335-818d-b5822e3fb884 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
The mean (SD) AUC(0 to 48) values were 54.6 (26.8) hr∙ng/mL and 53.1 (23.5) hr∙ng/mL, and corresponded to a bioavailability of 103% for the tablet relative to the solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a4e5046-293c-4616-8679-6da65f31626b (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
The mean (SD) AUC (0-48) values were 54.6 (26.8) and 53.1 (23.5) hr•ng/mL, and corresponded to a bioavailability of 103% for the tablet relative to the solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d810a15b-3e10-4f6c-a36e-8ddecbaba9c3 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
The mean (SD) AUC (0 to 48) values were 54.6 (26.8) and 53.1 (23.5) hr•ng/mL, and corresponded to a bioavailability of 103% for the tablet relative to the solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbf54709-5857-4dbc-9233-ebd7abff88c8 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
The mean (SD) AUC (0-48) values were 54.6 (26.8) and 53.1 (23.5) hr•ng/mL, and corresponded to a bioavailability of 103% for the tablet relative to the solution.
Projected row 1486
- Medicine slug
- terbutaline
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 0.545455
- Recorded readings
3.4 hours
- Numeric value
- 3.4
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:859267c6-3d14-4123-9b9d-4fc248f09726 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a95bc4f-34d3-4b5e-841b-6839e1c1e0c7 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:382dcebb-6e41-4335-818d-b5822e3fb884 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a4e5046-293c-4616-8679-6da65f31626b (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d810a15b-3e10-4f6c-a36e-8ddecbaba9c3 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbf54709-5857-4dbc-9233-ebd7abff88c8 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours.
2.9 hours
- Numeric value
- 2.9
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cec31032-f366-4524-9e01-63146e473b2b (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
Elimination half-life of the drug in 10 of 14 patients was approximately 2.9 hours after subcutaneous administration, but longer elimination half-lives (between 6 to 14 hours) were found in the other 4 patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f4d3249-e022-40b6-b93d-f605e8522207 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
Elimination half-life of the drug in 10 of 14 patients was approximately 2.9 hours after subcutaneous administration, but longer elimination half-lives (between 6 to 14 hours) were found in the other 4 patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a22b62c-4ee1-49df-e053-2a91aa0a3e52 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
Elimination half-life of the drug in 10 of 14 patients was approximately 2.9 hours after subcutaneous administration, but longer elimination half-lives (between 6 to 14 hours) were found in the other 4 patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:613df3cb-4d55-4d12-ab08-a932481aaa0b (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
Elimination half-life of the drug in 10 of 14 patients was approximately 2.9 hours after subcutaneous administration, but longer elimination half-lives (between 6 to 14 hours) were found in the other 4 patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f4b177e-4d7d-4255-afeb-522c7d4594c6 (opens source in a new tab)
Terbutaline label
Version not recorded · Effective date not recorded
Elimination half-life of the drug in 10 of 14 patients was approximately 2.9 hours after subcutaneous administration, but longer elimination half-lives (between 6 to 14 hours) were found in the other 4 patients.
Projected row 1487
- Medicine slug
- terconazole
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 0.833333
- Recorded readings
6.4 to 8.5 hours
- Numeric value
- 6.4
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b3923b5-0a97-428c-b8d2-4a3ceb3447a1 (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0a5e163-741f-4f5e-9d2e-b733f9879c99 (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71c13149-396e-edc6-e053-2a95a90af50c (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10e84353-93d2-461d-8b79-e9294df047ae (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e32bf0d-2a93-44ac-ae28-8d34e10380c0 (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d7a8fd6-7837-427e-9b18-89e33351b05e (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:207e9cf2-e8ec-43d7-9c11-46283c9cdb37 (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination - Across various studies in healthy women, after single or multiple intravaginal administration of terconazole, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4f50a11-bd39-4023-9145-2da60f6b085f (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b922feb5-cd85-4f13-9a18-913e58f8da83 (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38cd1718-6b3c-415d-a17f-7b399adb0ba2 (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Elimination Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours.
6.9 hours
- Numeric value
- 6.9
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f59448bd-f730-46d2-a785-c2d6205579ff (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Following oral (30 mg) administration of 14 C-labelled terconazole, the mean half-life of elimination from the blood for the parent terconazole was 6.9 hours (range 4.0-11.3).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b1c38ac-ebf3-471c-bcdf-1ff8ad197f91 (opens source in a new tab)
Terconazole label
Version not recorded · Effective date not recorded
Following oral (30 mg) administration of 14 C-labelled terconazole, the harmonic half-life of elimination from the blood for the parent terconazole was 6.9 hours (range 4.0-11.3).
Projected row 1488
- Medicine slug
- teriflunomide
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37f04f8b-001e-66ff-4574-cc34cebce61c (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4650d12c-b9c8-4525-b07f-a2d773eca155 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c1bc23b-a62b-4172-a603-8b97761514b4 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb431ea0-ba0f-4b5d-a50d-f8c050762242 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd80242-c607-4c50-b497-8259abb4a2f8 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d2724f6-8812-4a26-b2ec-936b71f868e1 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63ba28ef-5055-461a-99ef-c49e8ece4b54 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b25c24e-a4a9-43b4-a33f-75bef3a96d5f (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8219b4a2-fb9d-4387-ba33-96d28aad71dd (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c95ed7-130f-9455-e053-6394a90a182f (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbf32b27-e63a-4544-9c1f-6564e82200e5 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1824aae5-58af-43da-8231-435c8f118bc0 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (> 99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b084b44-f15b-4b16-b700-4382434f2136 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c424959d-00c9-4e76-aba6-cc7464d8e903 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:246d42e5-5418-42ba-aff9-ae399b166c69 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
Projected row 1489
- Medicine slug
- teriflunomide
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
11 L
- Numeric value
- 11
- Unit
- L
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37f04f8b-001e-66ff-4574-cc34cebce61c (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4650d12c-b9c8-4525-b07f-a2d773eca155 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c1bc23b-a62b-4172-a603-8b97761514b4 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb431ea0-ba0f-4b5d-a50d-f8c050762242 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd80242-c607-4c50-b497-8259abb4a2f8 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d2724f6-8812-4a26-b2ec-936b71f868e1 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63ba28ef-5055-461a-99ef-c49e8ece4b54 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b25c24e-a4a9-43b4-a33f-75bef3a96d5f (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8219b4a2-fb9d-4387-ba33-96d28aad71dd (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9c95ed7-130f-9455-e053-6394a90a182f (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbf32b27-e63a-4544-9c1f-6564e82200e5 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1824aae5-58af-43da-8231-435c8f118bc0 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b084b44-f15b-4b16-b700-4382434f2136 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c424959d-00c9-4e76-aba6-cc7464d8e903 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:246d42e5-5418-42ba-aff9-ae399b166c69 (opens source in a new tab)
Teriflunomide label
Version not recorded · Effective date not recorded
The volume of distribution is 11 L after a single intravenous (IV) administration.
Projected row 1490
- Medicine slug
- teriparatide
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
95%
- Numeric value
- 95
- Unit
- %
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d0c89a2-3849-adf6-007d-aeca21cf417c (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
AUC 0-t (pg∙hr/mL) 134.8 ± 79.7 83 AUC 0-inf (pg∙hr/mL) 149.8 ± 68.1 72 t 1/2 (hour) 0.79 ± 0.35 72 Absorption — Teriparatide is absorbed after subcutaneous injection; the absolute bioavailability is approximately 95% based on pooled data from 20-, 40-, and 80-mcg doses (1-, 2-, and 4-times the recommended dosage, respectively).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b007339-dd0d-f019-5e0a-9b1b0f75011c (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
AUC 0-t (pg∙hr/mL) 134.8 ± 79.7 83 AUC 0-inf (pg∙hr/mL) 149.8 ± 68.1 72 t 1/2 (hour) 0.79 ± 0.35 72 Absorption — Teriparatide is absorbed after subcutaneous injection; the absolute bioavailability is approximately 95% based on pooled data from 20-, 40-, and 80-mcg doses (1-, 2-, and 4-times the recommended dosage, respectively).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab322675-4769-45b0-b146-14fbaa3135d0 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption — Teriparatide is absorbed after subcutaneous injection; the absolute bioavailability is approximately 95% based on pooled data from 20-, 40-, and 80- mcg doses (1-, 2-, and 4- times the recommended dosage, respectively).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d371f0f7-d492-4481-b360-051456d56d65 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption - Teriparatide is absorbed after subcutaneous injection; the absolute bioavailability is approximately 95% based on pooled data from 20-, 40-, and 80- mcg doses (1-, 2-, and 4- times the recommended dosage, respectively).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d38b470a-2e62-487b-b3e7-134d3d1958b5 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption — Teriparatide is absorbed after subcutaneous injection; the absolute bioavailability is approximately 95% based on pooled data from 20-, 40-, and 80- mcg doses (1-, 2-, and 4- times the recommended dosage, respectively).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d3f65e2-e8f0-4d33-b79e-989013dd3ca3 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption — Teriparatide is absorbed after subcutaneous injection; the absolute bioavailability is approximately 95% based on pooled data from 20-, 40-, and 80- mcg doses (1-, 2-, and 4- times the recommended dosage, respectively).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aae667c5-381f-4f92-93df-2ed6158d07b0 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption — Teriparatide is absorbed after subcutaneous injection; the absolute bioavailability is approximately 95% based on pooled data from 20-, 40-, and 80- mcg doses (1-, 2-, and 4- times the recommended dosage, respectively).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d77d40db-7f38-88eb-fd5d-4282f0642028 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption — Teriparatide is absorbed after subcutaneous injection; the absolute bioavailability is approximately 95% based on pooled data from 20-, 40-, and 80- mcg doses (1-, 2-, and 4-times the recommended dosage, respectively).
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1480Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.